Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Adagene Inc./ 6-K

SEC Filing · 6-K

Adagene Inc.

SEC Filing

Filed Sep 22, 2026Accepted Sep 22, 2026, 8:00 AM EDTCIK 1818838Accession 0001104659-26-109485
View company →Permanent SEC source ↗
Share

Company context

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.

Current securities

ADAGNASDAQ · ADR · Current

Recent company filings

  1. 6-K filingSep 10, 2026
  2. 6-K filingSep 9, 2026
  3. 144/A filingAug 20, 2026
  4. 144 filingAug 19, 2026
  5. 4 filingAug 18, 2026

As-filed source

Primary evidence
As filedOpen full document ↗